YMAB - Y mAbs Therapeutics
Y mAbs Therapeutics Logo

YMAB - Y mAbs Therapeutics

https://www.ymabs.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
Neutral
Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB - Y-mAbs Therapeutics ( NASDAQ:YMAB )
Benzinga • 3 weeks, 5 days ago • score: 0.15
NEW YORK CITY and NEW ORLEANS, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ( "KSF" ) are investigating the proposed sale of Y-mAbs Therapeutics, Inc. YMAB to SERB Pharmaceuticals.
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-09 (Snapshot)

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of new antibody-based therapeutics for the treatment of cancer in the United States. The company is headquartered in New York, New York.

52W High
$16.11
52W Low
$3.55
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
0.53
Valuation
Rich
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
119.05
EV/EBITDA (<8 favorable)
-0.43
EV/Revenue (<3 favorable)
3.87
P/S (TTM) (<3 favorable)
4.57
P/B (<3 favorable)
4.46
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
11.97%
Institutions (25–75% balanced)
82.67%
Shares Outstanding
45,438,400
Float
18,891,500
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
85,385,000
Gross Profit (TTM)
69,582,000
EPS (TTM)
-0.50
Profit Margin (>10% good)
-0.26%
Operating Margin (TTM) (higher better)
-0.29%
ROE (TTM) (>15% strong)
-0.24%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-0.14
Momentum
Bearish momentum
Value
0.4667
Previous
0.4999
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025